Literature DB >> 8913847

Octreotide as first-line treatment for women with metastatic breast cancer.

J N Ingle1, C G Kardinal, V J Suman, J E Krook, A K Hatfield.   

Abstract

Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 micrograms subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8913847     DOI： 10.1007/bf00210797

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

2.  Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells.

Authors:  B Setyono-Han; M S Henkelman; J A Foekens; G M Klijn
Journal:  Cancer Res       Date:  1987-03-15       Impact factor: 12.701

3.  Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture.

Authors:  R W Furlanetto; J N DiCarlo
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

4.  A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.

Authors:  J N Ingle; J A Mailliard; D J Schaid; J E Krook; D H Gesme; H E Windschitl; D M Pfeifle; P S Etzell; J G Gerstner; H J Long
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

5.  Growth hormone regulates the abundance of insulin-like growth factor I RNA in adult rat liver.

Authors:  C T Roberts; A L Brown; D E Graham; S Seelig; S Berry; K H Gabbay; M M Rechler
Journal:  J Biol Chem       Date:  1986-08-05       Impact factor: 5.157

6.  Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.

Authors:  M V Dhodapkar; J N Ingle; S S Cha; J A Mailliard; H S Wieand
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860
  6 in total
  2 in total

1.  Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

Authors:  Young Kwang Chae; Mimi I Hu; Ruth L Katz; Mariana Chavez-MacGregor; Paul Haluska; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Amal Melhem-Bertrandt
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

2.  Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.

Authors:  K J O'Byrne; N Dobbs; D J Propper; J P Braybrooke; M I Koukourakis; K Mitchell; J Woodhull; D C Talbot; A V Schally; A L Harris
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.